可溶性Ninjurin-1的抗炎作用改善动脉粥样硬化
研究探讨了基质金属蛋白酶9底物Ninjurin-1(Ninj1)与动脉粥样硬化的关系。在冠心病患者和小鼠模型中,Ninj1表达与病变程度相关;Ninj1缺失加重炎症和单核细胞募集,而MMP9切割产生的可溶性Ninj1(sNinj1)具有抗动脉粥样硬化作用,其模拟肽ML56和PN12可减轻炎症和小鼠动脉粥样硬化。
要点
- Ninj1在动脉粥样硬化病变巨噬细胞中表达上调,与病变程度相关。
- Ninj1缺失通过激活MAPK和抑制PI3K/Akt促进巨噬细胞炎症,加重病变。
- sNinj1模拟肽ML56和PN12可减轻炎症和单核细胞募集,缓解小鼠动脉粥样硬化。
核心结论
- Ninj1是巨噬细胞中新型MMP9底物,sNinj1是分泌型动脉粥样硬化保护蛋白,调节巨噬细胞炎症和单核细胞募集。
研究设计与样本
- 研究评估了冠心病患者和健康对照的主动脉组织及血清样本,以及Apoe-/-和野生型小鼠的Ninj1表达与动脉粥样硬化进展。
- 生成全身Ninj1缺失的Ninj1-/-Apoe-/-小鼠和骨髓特异性Ninj1缺失的Ldlr-/-小鼠,喂食西方饮食5至23周。
- 用模拟sNinj1的肽ML56和PN12处理巨噬细胞和小鼠,验证Ninj1的抗炎作用。
主要发现
- 体内结果显示主动脉巨噬细胞Ninj1表达与人类和小鼠动脉粥样硬化病变程度相关。
- Ninj1缺陷巨噬细胞通过激活MAPK和抑制PI3K/Akt信号通路促进促炎基因表达。
- 全身和骨髓特异性Ninj1缺陷通过增强巨噬细胞介导的炎症显著增加病变内单核细胞募集和巨噬细胞积聚。
- 巨噬细胞Ninj1被MMP9直接切割生成可溶性形式,在体外和体内均显示抗动脉粥样硬化作用。
- ML56和PN12处理减少人和小鼠经典活化巨噬细胞的促炎基因表达,减轻单核细胞跨内皮迁移;持续给予mPN12可减轻小鼠动脉粥样硬化,无论Ninj1是否存在。
临床怎么用
- sNinj1及其模拟肽可能成为通过抑制炎症和单核细胞募集来治疗动脉粥样硬化的新策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Macrophages produce many inflammation-associated molecules, released by matrix metalloproteinases, such as adhesion molecules, and cytokines, as well, which play a crucial role in atherosclerosis. In this context, we investigated the relationship between Ninjurin-1 (Ninj1 [nerve injury-induced protein]), a novel matrix metalloproteinase 9 substrate, expression, and atherosclerosis progression. METHODS: Ninj1 expression and atherosclerosis progression were assessed in atherosclerotic aortic tissue and serum samples from patients with coronary artery disease and healthy controls, and atheroprone apolipoprotein e-deficient (Apoe-/-) and wild-type mice, as well. Apoe-/- mice lacking systemic Ninj1 expression (Ninj1-/-Apoe-/-) were generated to assess the functional effects of Ninj1. Bone marrow transplantation was also used to generate low-density lipoprotein receptor-deficient (Ldlr-/-) mice that lack Ninj1 specifically in bone marrow-derived cells. Mice were fed a Western diet for 5 to 23 weeks, and atherosclerotic lesions were investigated. The anti-inflammatory role of Ninj1 was verified by treating macrophages and mice with the peptides Ninj11-56 (ML56) and Ninj126-37 (PN12), which mimic the soluble form of Ninj1 (sNinj1). RESULTS: Our in vivo results conclusively showed a correlation between Ninj1 expression in aortic macrophages and the extent of human and mouse atherosclerotic lesions. Ninj1-deficient macrophages promoted proinflammatory gene expression by activating mitogen-activated protein kinase and inhibiting the phosphoinositide 3-kinase/Akt signaling pathway. Whole-body and bone marrow-specific Ninj1 deficiencies significantly increased monocyte recruitment and macrophage accumulation in atherosclerotic lesions through elevated macrophage-mediated inflammation. Macrophage Ninj1 was directly cleaved by matrix metalloproteinase 9 to generate a soluble form that exhibited antiatherosclerotic effects, as assessed in vitro and in vivo. Treatment with the sNinj1-mimetic peptides, ML56 and PN12, reduced proinflammatory gene expression in human and mouse classically activated macrophages, thereby attenuating monocyte transendothelial migration. Moreover, continuous administration of mPN12 alleviated atherosclerosis by inhibiting the enhanced monocyte recruitment and inflammation characteristics of this disorder in mice, regardless of the presence of Ninj1. CONCLUSIONS: Ninj1 is a novel matrix metalloproteinase 9 substrate in macrophages, and sNinj1 is a secreted atheroprotective protein that regulates macrophage inflammation and monocyte recruitment in atherosclerosis. Moreover, sNinj1-mediated anti-inflammatory effects are conserved in human macrophages and likely contribute to human atherosclerosis.
引用
- Jeon S, Kim TK, Jeong SJ, et al. Anti-Inflammatory Actions of Soluble Ninjurin-1 Ameliorate Atherosclerosis. Circulation. 2020. PMID: 32883094. doi:10.1161/CIRCULATIONAHA.120.046907
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。